Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xiaflex Sales Still Slow, But Other Indications In The Works

This article was originally published in The Pink Sheet Daily

Executive Summary

Auxilium’s Xiaflex sales still languish, but its older testosterone product continues to drive growth for the company.

You may also be interested in...

Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population

Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.

Auxilium Buys Actient As Base Business Weakens

The acquisition will establish Auxilium as a leading urology company and add nine commercial products. But the $585 million upfront acquisition price is expensive for Auxilium, as sales of its own products slump.

Auxilium Revamps Commercial Strategy For Xiaflex

The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts